Medindia LOGIN REGISTER
Medindia

Side effect(s) of Emicizumab


Review the side-effects of Emicizumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.

If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.

  Common:
Pain, itching or swelling at the injection site, headache, pain in the joints, fever

  Gastrointestinal:
Diarrhea, vomiting, stomach pain

  Cardiovascular:
Clot formation within blood vessels that can result in chest pain, thrombophlebitis (inflammation of veins), swelling of the arms or feet

  Central Nervous system:
Confusion, light-headedness, weakness

  Respiratory:
Coughing up blood, difficulty in breathing

  Skin:
Skin necrosis

  Others:
Vision problems, swelling or pain around eyes, back pain, reduced urination, numbness in the face, muscle pain

Other Precautions :

• Emicizumab may interfere with some laboratory tests. Test results should be confirmed with other diagnostic procedures or with clinical examination.
• The dose should be prepared only prior to administration.
• Do not shake the vial.
• Rotate the injection sites with no more than two injections at the same site to avoid burning sensation or irritation.
• Use a separate needle for injecting into the skin and avoid using the same needle which is used to draw the medicine from the vial.

Drug Name : Emicizumab

Emicizumab generic Emicizumab is a modified humanized monoclonal antibody which is prescribed to prevent or minimize the frequency of bleeding episodes in adults and children suffering from congenital factor VIII deficiency (known as hemophilia A), who have developed factor VIII inhibitors. Patients with hemophilia A have a missing clotting factor (factor VIII). These individuals are administered the factor VIII as an injection. Unfortunately, some individuals develop factor VIII inhibitors, which does not allow factor VIII to act. Emicizumab links the clotting factors activated IXA and X and thus replaces the function of the factor VIII, and ensures the normal clotting of the blood.


Advertisement